Roseman · Journal of psychopharmacology (Oxford, England) 2019 · prospective observational psychometric validation study · n=379

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.

Cited 426 times in the scientific literature.

Level 4 - case-series / case-control

Prospective observational survey study without a control group

PubMed 31294673 · doi:10.1177/0269881119855974 · record verified 2026-08-28

What was done

Participants (n = 379) completed prospective online surveys before and after an intended psychedelic experience. One day post-experience, participants completed candidate items for emotional breakthrough alongside validated measures: the Mystical Experience Questionnaire (MEQ) and the Challenging Experience Questionnaire (CEQ). Factor analysis was conducted to establish scale structure. In a subset of participants with low baseline well-being (Warwick-Edinburgh Mental Wellbeing Scale score <=45; n = 75), the ability of emotional breakthrough, MEQ, and CEQ scores to predict post-experience changes in well-being was evaluated.

What was found

Factor analyses isolated a six-item measure termed the Emotional Breakthrough Inventory (EBI) with high internal consistency (Cronbach's alpha = 0.932). EBI scores were higher with therapeutic planning/intent and showed a dose-dependent pattern. In the low baseline well-being subgroup (n = 75), combined scores of EBI, MEQ, and CEQ significantly predicted subsequent changes in well-being (r = 0.45, p = 0.0005), with EBI and MEQ scores positively predicting increases in well-being, whereas CEQ scores predicted smaller increases.

Why it matters

This study introduces and validates the Emotional Breakthrough Inventory, demonstrating that acute emotional resolution is a distinct, measurable psychometric dimension of the psychedelic state that contributes to positive psychological outcomes alongside mystical experiences.

Limits

The study relied on self-selected online survey respondents taking unstandardized psychedelics in uncontrolled settings. The predictive validation for well-being changes was restricted to a small subsample (n = 75). Lacks randomized control groups, objective verification of substance or dosage, and clinical diagnostic assessments.

Cited by